Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0113-6861 · 1 trial · 2 indications
hours
| Arm | Type | Description |
|---|---|---|
| Study compound 1 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 1 |
| Study compound 2 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 2 |
| Study compound 3 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 3 |
| Name | Type | Description |
|---|---|---|
| NNC0113-6861 | DRUG | Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861 |
| NNC0113-6860 | DRUG | Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860 |
| NNC0113-6891 | DRUG | Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891 |
Inclusion Criteria: * Healthy subject. * Sex : Male. * Age 18 to 54 years, inclusive, at the time of signing informed consent. * Body mass index (BMI) 18.0 to 30.0 kg/m\^2, inclusive, at the time of signing informed consent . Exclusion Criteria: * Known or suspected hypersensitivity to study prod...
NNC0113-6861 is an investigational small molecule being developed by Novo Nordisk for metabolic conditions. It is currently in Phase 1 clinical development, studied in healthy volunteers and individuals with Type 2 Diabetes. The drug is not yet approved and remains in early-stage clinical testing.
NNC0113-6861 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's properties in healthy volunteers and people with Type 2 Diabetes.
NNC0113-6861 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a single completed Phase 1 trial involving 18 participants, with no active trials currently ongoing.
NNC0113-6861 has one completed clinical trial, registered as NCT04676906. This Phase 1 study investigated the distribution and metabolism of three 14C-labeled radioactive study compounds, including NNC0113-6861, in healthy male volunteers and individuals with Type 2 Diabetes. The trial was conducted in the Netherlands.
No alternative names for NNC0113-6861 have been disclosed. The drug is identified solely by its code name NNC0113-6861 in clinical trial registrations and development records.